Streetbeat News

Analyst Ratings

RVNC

Needham analyst Serge Belanger has maintained a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC), but lowered the price target from $44 to $40.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:54 am

TWLO

Needham analyst Ryan Koontz maintains a Buy rating on Twilio (NYSE:TWLO) and raises the price target from $65 to $75.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:53 am

RNA

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Avidity Biosciences (NASDAQ:RNA) and maintained a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:52 am

JAMF

Needham analyst Joshua Reilly has reiterated a 'Buy' rating on Jamf Holding (NASDAQ:JAMF) and maintained a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:52 am

ARVN

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Arvinas (NASDAQ:ARVN) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:51 am

DNLI

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a price target of $105.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:45 am

CCCC

HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on C4 Therapeutics (NASDAQ:CCCC) but lowers the price target from $25 to $17.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:44 am

OLMA

HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Olema Pharmaceuticals and raises the price target from $17 to $22.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:44 am

XERS

HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Xeris Biopharma Holdings (NASDAQ:XERS) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:42 am

PHAT

HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:41 am